Grant Revenue	6 Months Ended
Jun. 30, 2022
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Grant Revenue [Line Items]
Grant Revenue	7. GRANT REVENUE In July 2020, the Company was approved to receive a grant from the Bill & Melinda Gates Foundation in the amount of approximately $3.3 million. As of December 31, 2021, the Company had received the entire grant award, of which approximately $2.4 million was received during the year ended December 31, 2020, and the remaining approximately $0.9 million was received during the year ended December 31, 2021. The grant funds are to be used for the sole purpose of research for in vivo gene therapy for sickle cell disease and to explore new, low-cost capabilities for the in vivo functional cure of sickle cell and or durable suppression of HIV in developing countries. The Company incurred research and development costs of approximately $16 thousand and $0.3 million associated with this grant for the three and six months ended June 30, 2022, respectively and $0.4 million and $0.7 million for the three and six months ended June 30, 2021, respectively. The Company has recognized revenue of approximately $20 thousand and $0.3 million for the three and six months ended June 30, 2022, respectively and $0.5 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The unearned balance of approximately $0.7 million and $1.3 million is recorded as deferred revenue in the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively. The research supported by this grant is expected to be completed by the end of 2022.

Grant Revenue

6 Months Ended

Jun. 30, 2022

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]

7. GRANT REVENUE

In July 2020, the Company was approved to receive a grant from the Bill & Melinda Gates Foundation in the amount of approximately $3.3 million. As of December 31, 2021, the Company had received the entire grant award, of which approximately $2.4 million was received during the year ended December 31, 2020, and the remaining approximately $0.9 million was received during the year ended December 31, 2021. The grant funds are to be used for the sole purpose of research for in vivo gene therapy for sickle cell disease and to explore new, low-cost capabilities for the in vivo functional cure of sickle cell and or durable suppression of HIV in developing countries. The Company incurred research and development costs of approximately $16 thousand and $0.3 million associated with this grant for the three and six months ended June 30, 2022, respectively and $0.4 million and $0.7 million for the three and six months ended June 30, 2021, respectively. The Company has recognized revenue of approximately $20 thousand and $0.3 million for the three and six months ended June 30, 2022, respectively and $0.5 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The unearned balance of approximately $0.7 million and $1.3 million is recorded as deferred revenue in the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively. The research supported by this grant is expected to be completed by the end of 2022.